Where can I buy Adagrasib in China?

Adagrasib is a targeted therapy that belongs to a class of drugs known as KRAS G12C inhibitors. KRAS G12C is a cancer-related mutant that is associated with a variety of malignant tumors such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. This mutation allows tumor cells to proliferate, grow and spread excessively, making treatment more difficult.

Since adagrasib has not yet been launched in China, patients cannot purchase it directly domestically and must resort to overseas channels. At present, the original adagrasibu drug in foreign countries is mainly produced in the United States, but the price is extremely expensive, reaching more than 180,000 yuan, which makes it difficult for ordinary families to afford it.

However, the good news is that generic drugs have recently come out abroad. For example, the generic drug of adagrasibu produced by Lucius in Laos costs about 4,000 to 5,000 yuan per box, which is significantly lower than the price of the original drug. After testing, the generic drug is basically consistent with the original drug in terms of drug ingredients.

The unique feature of adagrasib is its ability to targetKRAS G12C mutation, which provides new hope for tumor treatment. By inhibiting the activity of this mutant, it blocks the growth signaling of cancer cells, thereby inhibiting tumor growth and spread.

Clinical trials have shown that adagrasib exhibits significant anti-tumor activity in some patients with advanced cancer. Although further studies are still needed to determine its long-term efficacy and safety, adagrasib offers a new treatment option for those with the KRAS G12C mutation, particularly those who have previously lacked effective treatments.

However, as with all medications, adagrasiib has some side effects and risks. Common side effects may include nausea, vomiting, fatigue, digestive problems such as diarrhea, as well as headaches, high blood pressure, and more. Therefore, when using adagrasib, physicians need to carefully weigh the potential benefits and risks and monitor closely with patients.